This inventor holds 6 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: American Biogenetic Sciences, Inc., University College Dublin, Daiichi Pharmaceutical Co., Ltd.. Active years: 1997-2013.
Company Filing History:
2 out of 23 
2 out of 121 
1 out of 200 Years Active: 1997-2013
Title: Ciaran M Regan: Innovator in Psycho-Pharmaceuticals
Introduction
Ciaran M Regan is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of psycho-pharmaceuticals, holding a total of 6 patents. His work focuses on developing innovative treatments for mental health disorders and cognitive impairments.
Latest Patents
One of his latest patents involves a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand. This invention aims to treat symptoms of anxiety and/or depression associated with affective disorders, as well as cognitive impairment disorders. Notably, diphenhydramine derivatives of Formula (I), particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) known as Captodiamine, are highlighted in this patent. Another significant patent includes benzoquinolizidine and benzoindolizidine derivatives, which are useful for treating Alzheimer's disease, senile dementia, and other conditions characterized by memory loss. Pharmaceutical compositions containing these compounds and methods for their use are also provided.
Career Highlights
Ciaran has worked with prominent organizations such as American Biogenetic Sciences, Inc. and University College Dublin. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative pharmaceutical solutions.
Collaborations
Ciaran has collaborated with notable professionals in his field, including Heinz Nau and David O'Gorman. These partnerships have further enriched his research and development efforts.
Conclusion
Ciaran M Regan is a distinguished inventor whose work in psycho-pharmaceuticals has the potential to significantly impact the treatment of mental health disorders. His innovative patents and collaborations reflect his commitment to advancing medical science.